Novartis's Next Prostate Cancer Therapy Could Raise Bar for Treatment -- Market Talk

Dow Jones06-01

0849 GMT - Novartis is developing an experimental therapy that could raise the bar for the treatment of prostate cancer, Vontobel's Stefan Schneider says in a research note. The Swiss drugmaker released data from an early-stage clinical trial for its 225Ac-PSMA-617 drug candidate that showed so-called alpha particle radioactive isotopes should work in fighting prostate cancer, the analyst says. The new therapy differs from Novartis's approved Pluvicto prostate-cancer treatment in the radioisotope it uses to kill cancer cells, Vontobel says. Pluvicto carries a beta particle that travels for a longer range but is less lethal, while the new therapy uses an alpha particle that is more lethal but travels shorter distances, the analyst says. Deploying both could raise the bar for the treatment of prostate cancer, he adds. Shares fall 1.9%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

June 01, 2026 04:49 ET (08:49 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2640932143?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 16:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640932143","market":"hk","top_or_hot":-1,"title":"Novartis's Next Prostate Cancer Therapy Could Raise Bar for Treatment -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0849 GMT - Novartis is developing an experimental therapy that could raise the bar for the treatment of prostate cancer, Vontobel's Stefan Schneider says in a research note. The Swiss drugmaker released data from an early-stage clinical trial for its 225Ac-PSMA-617 drug candidate that showed so-called alpha particle radioactive isotopes should work in fighting prostate cancer, the analyst says. The new therapy differs from Novartis's approved Pluvicto prostate-cancer treatment in the radioisotope it uses to kill cancer cells, Vontobel says. Pluvicto carries a beta particle that travels for a longer range but is less lethal, while the new therapy uses an alpha particle that is more lethal but travels shorter distances, the analyst says. Deploying both could raise the bar for the treatment of prostate cancer, he adds. Shares fall 1.9%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 01, 2026 04:49 ET (08:49 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis's Next Prostate Cancer Therapy Could Raise Bar for Treatment -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis's Next Prostate Cancer Therapy Could Raise Bar for Treatment -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-01 16:49</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0849 GMT - Novartis is developing an experimental therapy that could raise the bar for the treatment of prostate cancer, Vontobel's Stefan Schneider says in a research note. The Swiss drugmaker released data from an early-stage clinical trial for its 225Ac-PSMA-617 drug candidate that showed so-called alpha particle radioactive isotopes should work in fighting prostate cancer, the analyst says. The new therapy differs from Novartis's approved Pluvicto prostate-cancer treatment in the radioisotope it uses to kill cancer cells, Vontobel says. Pluvicto carries a beta particle that travels for a longer range but is less lethal, while the new therapy uses an alpha particle that is more lethal but travels shorter distances, the analyst says. Deploying both could raise the bar for the treatment of prostate cancer, he adds. Shares fall 1.9%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 01, 2026 04:49 ET (08:49 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0009355771.USD","symbol_name":"骏利亨德森环球生命科技A Acc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2640932143","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640932143","pubTimestamp":1780303740,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0849 GMT - Novartis is developing an experimental therapy that could raise the bar for the treatment of prostate cancer, Vontobel's Stefan Schneider says in a research note. The Swiss drugmaker released data from an early-stage clinical trial for its 225Ac-PSMA-617 drug candidate that showed so-called alpha particle radioactive isotopes should work in fighting prostate cancer, the analyst says. The new therapy differs from Novartis's approved Pluvicto prostate-cancer treatment in the radioisotope it uses to kill cancer cells, Vontobel says. Pluvicto carries a beta particle that travels for a longer range but is less lethal, while the new therapy uses an alpha particle that is more lethal but travels shorter distances, the analyst says. Deploying both could raise the bar for the treatment of prostate cancer, he adds. Shares fall 1.9%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4532":"文艺复兴科技持仓","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4007":"制药","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","BK4588":"碎股","NVS":"诺华","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4578":"CAR-T","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC"},"translate_title":"诺华的下一种前列腺癌疗法可能会提高治疗标准——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVS":0.9},"content_text":"0849 GMT - Novartis is developing an experimental therapy that could raise the bar for the treatment of prostate cancer, Vontobel's Stefan Schneider says in a research note. The Swiss drugmaker released data from an early-stage clinical trial for its 225Ac-PSMA-617 drug candidate that showed so-called alpha particle radioactive isotopes should work in fighting prostate cancer, the analyst says. The new therapy differs from Novartis's approved Pluvicto prostate-cancer treatment in the radioisotope it uses to kill cancer cells, Vontobel says. Pluvicto carries a beta particle that travels for a longer range but is less lethal, while the new therapy uses an alpha particle that is more lethal but travels shorter distances, the analyst says. Deploying both could raise the bar for the treatment of prostate cancer, he adds. Shares fall 1.9%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 01, 2026 04:49 ET (08:49 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640932143","isCrawlerRequest":true}